See discussions, stats, and author profiles for this publication at: https://www.researchgate.

net/publication/272820065

ANTIBIOTICS

Chapter · January 2015

DOI: 10.13140/RG.2.1.5114.4804

CITATIONS READS
0 52,480

2 authors:

Salma Jum'a Rafik Karaman

Al-Quds University Al-Quds University
13 PUBLICATIONS   35 CITATIONS    272 PUBLICATIONS   3,840 CITATIONS   

SEE PROFILE SEE PROFILE

Some of the authors of this publication are also working on these related projects:

Treatment of grey- and waste-water by novel adsorbents View project

Design & Synthesis of Novel Prodrugs View project

All content following this page was uploaded by Rafik Karaman on 13 March 2015.

The user has requested enhancement of the downloaded file.

 In: Commonly Used Drugs ISBN: 978-1-63463-828-9
Editor: Rafik Karaman © 2015 Nova Science Publishers, Inc.

c.
Chapter 2

In
Antibiotics

rs
Salma Jumaa1 and Rafik Karaman1,2
1
Pharmaceutical Sciences Department,
Faculty of Pharmacy Al-Quds University,

he
Jerusalem, Palestine
2
Department of Science, University of Basilicata,
Potenza, Italy
is
Abstract
Antibiotics are the most active chemotherapeutics among drugs; they exert their
bl
therapeutic effect by antagonizing the growth of bacteria. Since 1910 many antibiotics
have been developed with different mechanisms of action including: (1) inhibition of
bacteria‘s cell wall synthesis; this class of antibiotics includes vancomycin and β-lactam
antibiotics such as penicillins, cephalosporins and carbapenems, (2) inhibition of protein
Pu

synthesis including tetracyclines, aminoglycosides, macrolides and chloramphenicol and

(3) DNA synthesis inhibitors such as fluoroquinolones and sulfonamides that inhibit folic
acid synthesis. In this chapter we describe the three antibiotic classes, their mechanism of
action, clinical uses, side effects, and their resistance by different bacteria.

Keywords: antibiotics, cell wall synthesis inhibitors, penicillins, β-lactam antibiotics,

mechanism of action, cephalosporins, side effects, protein synthesis inhibitors, protein
a

synthesis inhibitors, bacterial resistance

ov

Abbreviations
PBP Penicillin binding proteins
DHP1 Human renal dehydrogenase 1
N

I.V Intravenous
UTI Urinary tract infection
G.I Gastrointestinal
 42 Salma Jumaa and Rafik Karaman

AMP Adenosine monophosphate

STD Sexually transmitted diseases

History

c.
Infections were the major cause of death during the nineteenth century. The introduction
of antibiotics not only helped in the treatment of infections but also have a major role in

In
decreasing mortality and morbidity.
In 1910 Paul Ehrlich developed the first antimicrobial salvarsan for the treatment of
syphilis, a disease that was almost incurable back then [1]. In 1932 prontosil, a sulfonamide
antibiotic was discovered and since it was cheap, many companies were encouraged to mass
produce many derivatives of prontosil [2].

rs
During the second half of the nineteenth century and before the important discovery of
Fleming many researchers recorded observations regarding the antibacterial properties of
penicillium fungi [2]. In 1929, Alexander Fleming introduced "penicillin" as a compound
with antibacterial properties, when he observed that a bacterial growth was terminated by a

he
mold, however, because prontosil was available there was not much interest in penicillin. Till
1941, the purity of extracted penicillin was only 0.3 to 7%, which was not sufficient to be
clinically used. In 1945, Dorothy (Crowfoot), Hodgkin and Barbara Low used x-ray
crystallography to determine the chemical structure of penicillin and in 1950 penicillin was
chemically synthesized [3]. The isolation of 6-aminopenicillanic acid (Figure 1) in 1958 led
is
to the semisynthesis of new penicillins such as ampicillin, methicillin and carbenicillin [3].
Few years later, ticarcillin (1971) and piperacillin (1977) were synthesized and in 1989 the
combination of piperacillin- tazobactam was introduced and was widely used because of its
bl
high activity against gram positive bacteria [4].

O
Pu

H2N

N OH
a

H
ov

S
O
N

Figure 1. Chemical structure of 6-aminopenicillanic acid.

 Antibiotics 43

Selman Waksman, a soil microbiologist, and coworkers isolated the first aminoglycoside
streptomycin which was effective against tuberculosis, the main cause of death in the 19th
century [5]. In 1953, Newton and Abraham discovered cephalosporin C; its antibacterial
activity was low but was not susceptible to hydrolysis by penicillinase. Cephalothin, the first
cephalosporin available for clinical use, was introduced in 1964, but it was only available for

c.
parenteral use [4]. Lilly Research Laboratories developed cephalexin, which was effective
upon oral administration and total synthesis of cephalosporin C was accomplished in 1970.
Beecham laboratories discovered β-lactamases inhibitors and Merck developed thienamycin
antibiotic which was followed by the discovery of sulfazecin, the monocyclic β-lactam

In
antibiotic, by Takeda Chemical Industries [3].

Cell Wall Synthesis Inhibitors

rs
Penicillin binding proteins (PBP) are bacterial proteins that bind covalently to penicillins
and other β-lactam antibiotics. These antibiotics bind and acylate the binding site of PBP
leading to inhibition of cell wall synthesis [6].

he
Β - Lactam Antibiotics
β-lactam antibiotics have wide spectrum of activity and low toxicity because the drug
is
targets bacterial cell wall that has no analogues in higher organisms.
bl
Mechanism of Action
The inhibition of cell wall synthesis leads to loss of osmotic support and eventually cell
Pu

lysis. The last step in cell wall synthesis is the cross linking of peptidoglycans between the
carboxyl of D-alanine in one peptidoglycan chain and an amino group in the next chain, this
reaction is catalyzed by transpeptidase. The cross linking of the adjacent glycan chains causes
the rigidity of the cell wall. Binding of penicillin to the transpeptidase enzyme forms an acyl
enzyme complex via the penicillin β-lactam ring cleavage, which leads to transpeptidase
enzyme inactivation and eventually cell lysis [7]. Few novel antibacterial drugs were
synthesized in the past few years, some of these drugs are inhibitors of peptidoglycan
a

synthesis, such as MurA inhibitors; MurA is an enzyme that catalyses the first step in
peptidoglycan synthesis, the natural fosfomycin is an irreversible inhibitor of this enzyme.
ov

Inhibitors of MurB, MurC, MurD and MurE were developed as well [8].

Penicillins
N

Penicillins are the oldest available antibiotics, their bacterial activity is due to the
inhibition of cell wall synthesis, despite the development of resistance penicillins remain the
 44 Salma Jumaa and Rafik Karaman

most useful antibiotics today. Natural penicillins have narrow spectrum of activity while the
newer penicillins have wide spectrum, they are effective against many gram negative bacteria
such as H influenza and E coli. Penicillins are effective in the treatment of nose, throat, lower
respiratory tract and genitourinary tract soft tissue infections [9].
Penicillin G (Figure 2) is natural penicillin with narrow spectrum of activity, short half

c.
life of 30-60 minutes and easily inactivated by gastric secretions, which makes it mostly used
in parenteral administration. Bezathine penicillin is a slow release form of penicillin G and is
used for the treatment of early and late stage syphilis as I.M injection [9].

In
Penicillin V (Figure 3) is natural penicillin that is used orally because of its stability in
the gastric secretions.
Synthetic penicillins were developed because of the emergence of resistance due to β-
lactamases.

H H

rs
N
S

N
he
O
O
is
O
bl
OH Penicillin G
Figure 2. Chemical structure of penicillin G.
Pu

H H
N
S O
a

O
ov

N
O
HO
N

O Penicillin V
Figure 3. Chemical structure of penicillin V.
 Antibiotics 45

Ampicillin (Figure 4) was the first penicillin in this category, developed by the addition
of an amino group to benzylpenicillin. Ampicillin is available as oral and parenteral dosage
forms and is administered every 6 hours. Amoxicillin (Figure 5) replaced ampicillin because
of better absorption when administered orally, bioavailability of 95%, dosing every 8 hours
and less G.I side effects. Both ampicillin and amoxicillin are used as prophylaxis before

c.
genitourinary and gastrointestinal procedures and prophylaxis against bacterial endocarditis.
Further, both penicillins have broader spectrum than the natural penicillins [9]. In the case of
chronic bronchitis, H. influenza infections and H. influenza meningitis amoxicillin is the drug

In
of choice [10].

rs
he
H H
N
S NH2
is
N O

O
bl
HO
O Ampicillin
Pu

Figure 4. Chemical structure of ampicillin.

H2N O O
O
a

HN N
OH
ov

H
S

HO
N

Amoxicillin
Figure 5. Chemical structure of amoxicillin.
 46 Salma Jumaa and Rafik Karaman

c.
In
Figure 6. Chemical structure of β-lactamase inhibitors.

rs
he
is
bl
Pu
a
ov
N

Figure 7. Chemical structures of ticarcillin, carbenicillin, azlocillin and piperacillin.

 Antibiotics 47

The development of bacterial β-lactamases caused inactivation and resistance to β-lactam

antibiotics. Clavulanic acid, sulbactam and tazobactam (Figure 6) are suicidal inhibitors that
bind irreversibly to β-lactamase enzymes. Amoxicillin-clavulanic acid was the first β-lactam-
β-lactamase combination introduced into clinical practice [11]. This combination is the only
orally available and most widely used in skin and intra-abdominal infections. Ampicillin-

c.
sulbactam and piperacillin-tazobactam are available only for intravenous administration [9].
Carboxypenicillins are extended spectrum penicillins such as ticarcillin, carbenicillin,
azlocillin and piperacillin (Figure 7), they are used for the treatment of complicated infections

In
[9].

Side Effects of Penicillins

rs
Penicillins are the safest among all antibiotics; they are classified by the FDA as
pregnancy category B and are safe for use in breastfeeding women. The most common side
effect and allergic symptom is skin rash. In the case of ampicillin G.I side effects are the most
common. Candidiasis is common in the use of broad spectrum penicillins. Allergy and

he
hypersensitivity are also common side effects which may cause anaphylaxis [9].

Cephalosporins
is
Cephalosporins are a large group of β-lactam antibiotics with broad spectrum of activity,
compared to older antibiotics cephalosporins have good pharmacokinetic profile and low drug
toxicity. Based on their spectrum of activity they are classified into four generations [12].
bl
Semisynthetic cephalosporins are produced by modifications on cephalosporin C
molecule (Figure 8). Substitutions on C7 result in providing compounds with more stability
against β-lactamases, which caused increase in activity and broader spectrum such as
cefuroxime, cefotaxime, ceftriaxone and ceftazidime. Substitutions on C3 yield compounds
Pu

with longer half life such as in the case of ceftriaxone and ceftazidime [12].
Cephalosporins like other β-lactam drugs bind to the PBP by covalent bond and
inactivate transpeptidase enzymes, leading to inhibition of the cell wall synthesis [12].

O OH
O
a

NH2 N O
O
ov

HO
S
N
H H
N

O
cephalosporin C
Figure 8. Chemical structure of cephalosporin C.
 48 Salma Jumaa and Rafik Karaman

First Generation Cephalosporins

The first generation cephalosporins were introduced to clinical practice in 1960.

Antibiotics of this generation are most active against aerobic gram positive cocci [12]. They
include cephalothin (Figure 9), which has a short half life of 0.67 hour [12] and cephaloridine

c.
(Figure 10) that causes nephrotoxicity. Both have a broad spectrum of activity but they are
susceptible to β-lactamases and ineffective against gram negative bacteria [13]. This
generation also includes cephalexin and cefaclor (Figure 11) that are administered orally three
to four times daily, they are absorbed in the brush border membrane of the small intestine via

In
a dipeptide transporter, these drugs are best to be administered on empty stomach [12].

Second Generation Cephalosporins

rs
The second generation cephalosporins are more stable against β-lactamases but not
effective against some gram negative bacilli [13]. Cefoxitin and cefotetan (Figure 12) are
more active against anaerobic bacteria [12].

he
HO O
O
O
N O
is
O
S
N S
bl
H H

Cephalothin
Pu

Figure 9. Chemical structure of cephalothin.

-
O O

O
a

N N+
O
ov

S
S
N
H H
N

Cephaloridine
Figure 10. Chemical structure of cephaloridine.
 Antibiotics 49

c.
H H NH2
N H H NH2
S N
S
O
O

In
N
N
O Cl
O

O OH
O OH
Cephalexin Cephaclor

rs
Figure 11. Chemical structures of cephalexin and cephaclor.

he S
is
H HN O
S
O
bl
H2N O N
O

O
Pu

HO O

Cephoxitin
N N
N
N S O O-
a

Na+

S NH2
S
ov

- H
O H
Na+ N N
S O

O
O O
O
N

Cephotetan

Figure 12. Chemical structures of cephoxitin and cephotetan second generation cephalosporins.
 50 Salma Jumaa and Rafik Karaman

Third Generation Cephalosporins

The third generation cephalosporins such as cefotaxime (Figure 13), ceftazidime,

cefdinir, cefixime and ceftriaxone are more stable against many β-lactamases and has a
broader specrum of activity [14].

c.
Ceftazidime (Figure 14) is highly effective against aerobic gram negative bacteria and
most active against pseudomonas aeruginosa [12]. The half life of ceftazidime is 1.9 hours, it
is excreted unchanged in the urine [13].

In
NH2

S
N

rs
O
H H N
N

he
S

O
O N
O
is
O
O OH
bl
Cefotaxime
Figure 13. Chemical structure of cefotaxime.
Pu

NH2

S
N HO
O

O
a

H H N
N
S
ov

O
N+ N
O

-O O
N

Cephtazidime

Figure 14. Chemical structure of cephtazidime.

 Antibiotics 51

Cefdinir (Figure 15) was approved by the FDA in 1997. Diarrhea is the main side effect
of cefdinir, it is mainly excreted by kidneys and has a half life of approximately 1.5 hours
[15].
Cefixime (Figure 16) can be administered once daily because it has a half life of three to
four hours, which is the longest half life of the orally administered cephalosporins [12].

c.
Ceftriaxone (Figure 17) is administered parenterally and has the longest half life of all β-
lactam drugs, it is administered once daily [12].

NH2

In
S
N

rs
OH
H H N
S N

N
he O
O
is
O OH
Cefdinir
bl
Figure 15. Chemical structure of cefdinir.

NH2
Pu

S
N OH

O
H H N
a

S N

O
ov

N
O

HO O
N

Cefixime
Figure 16. Chemical structure of cefixime.
 52 Salma Jumaa and Rafik Karaman

Fourth Generation Cephalosporins

The fourth generation cephalosporins were developed by the addition of a quaternary

ammonium group at the C3 position, which makes zwitterionic compounds with the ability to
penetrate gram negative bacterial outer membrane [12]. These compounds are parenterally

c.
administered and have a broader specrum of activity than the third generation. They are active
against both gram positive and gram negative organisms, more effective and have more
stability against some β-lactamases. This generation includes cefpirome and cefepime (Figure
18). These antibiotics are given twice daily, and used for the treatment of nosocomial

In
infections specially in intensive care units [14].

H
N
N
O

rs
S
N
O S S NH2
H

he
N NH N
O

OH
O O N O
Cefriaxone
is
Figure 17. Chemical structure of ceftriaxone.

O
O
bl
O O-
N
O
N
N
H
Pu

N H S N+

S
H2 N

Cefpirome

NH2
S
a

N
N+
S H
ov

S N
H O
N
- N NH N O
O

O
O O N O
N

Cefipime

Figure 18. Chemical structures of cefpirome and cefipime.

 Antibiotics 53

Cefpirome has a half life of two hours; it is mainly excreted by the kidneys. The most
common side effect is diarrhea, others are rash and nausea. Cefpirome is used for the
treatment of respiratory tract infections, complicated urinary tract infections, skin and soft
tissue infections, sepsis, bacterial meningitis, fever associated with neutropenia, and
combined with metronidazole for intraabdominal infections [14].

c.
Cephalosporins Clinical indications

In
Second and third generations of cephalosporins are effective in community acquired
pneumonia.
For bacterial meningitis, third generation cephalosporins such as ceftriaxone and
cefotaxime are drugs of choice. Ceftazidime or cefepime are the initial treatment in a patient
with neutropenia and fever. Cephalosporins are also effective in the treatment of gonorrhea,

rs
syphilis, surgical prophylaxis and bacterial endocarditis [12].
The excretion of all orally administered cephalosporins is renally, except for cefixime, in
which 50% of the dose is excreted in the urine [12].

Adverse Effects of Cephalosporins

he
Orally administered cephalosporins may cause G.I side effects including nausea,
is
vomiting and diarrhea. Allergic reactions affect 1 to 3% of patients taking cephalosporins.
Cephalosporins cause transient, mild increase in hepatic transaminases enzymes in 1 to 7% of
patients [12].
The development of bacterial resistance limits the use of cephalosporins, the mechanisms
bl
of resistance include synthesis of β-lactamases, alteration in the PBP target and change in the
bacterial cell membrane porins [12].
Pu

Masking Bitter Taste of Amoxicillin and Cephalexin

Masking bitter taste is crucial for patient compliance especially in pediatric and geriatric
patients.
Prodrug approach has been used for masking amoxicillin and cephalexin bitter taste. It is
expected that by blocking the free amine group in amoxicillin and cephalexin by a suitable
a

linker the interaction of the antibacterial with bitter taste receptors on the tongue will be
blocked.
ov

Based on this theory Karaman's group synthesized cephalexin and amoxicillin prodrugs
(Figure 19) [16].
N
 54 Salma Jumaa and Rafik Karaman

O
O

OH
O OH
HN
HN O
H

c.
H HN NH
S
S
O
N O
N OH

In
O O
O
OH
HO O Cephalexin prodrug Amoxicillin prodrug

Figure 19. Chemical structures of cephalexin and amoxicillin prodrugs.

rs
Carbapenems

he
Carbapenems are broad spectrum β-lactam antibiotics; they are stable to almost all β-
lactamases. They differ from other β-lactam antibiotics in their nuclear structure, in which the
sulfur is replaced by a carbon group and there is an unsaturated bond between carbon 1 and 3
in the thiazolidine moiety (Figure 20) [17].
is
O
bl

N
Pu

O
OH
Figure 20. Basic chemical structure of carbapenems.

The first carbapenem introduced into clinical practice was imipenem (Figure 21); it has a
a

broad specrum of activity but was susceptible to hydrolysis by human renal dehydrogenase 1.
Then meropenem (Figure 22) was developed, the side chain on the C2 yielded a stable
compound to the DHP1 enzyme. Imipenem and meropenem are both administered via I.V
ov

injection. Meropenem is more active against gram negative bacteria than imipenem, while the
latter is more active against gram positive bacteria. Both are active against lower respiratory
tract infections. Meropenem is the only carbapenem that was evaluated in children and is
FDA approved to be used in paediatric meningitis. Other carbapenems are ertapenem,
N

panipenem, biapenem, lenapenem and sanfetrinem [17].

 Antibiotics 55

HO
O
O
N

c.
S

In
N
OH
NH2
Imipenem

rs
Figure 21. Chemical structure of imipenem.

HO

he
O
O
N
S
is
HO
H
N
bl
N
H
O
Pu

Meropenem
Figure 22. Chemical structure of meropenem.

Vancomycin
a

This glycopeptide antibiotic (Figure 23) was developed in 1950, the basic structure of this
type of antibiotics is seven amino acids, sugars and amino sugars [18]. Vancomycin inhibits
ov

cell wall synthesis by forming a complex with peptidoglycan which inhibits transpeptidase
[19].
Vancomycin is used for the treatment of infections caused by gram positive bacteria. It is
used for staphylococcus epidermis, methicillin resistance staphylococcus aurius (MRSA),
endocarditis caused by methicillin resistance staphylococcus aurius and methicillin sensitive
N

staphylococcus aurius and staphylococcus central nervous system infections. However,

linezolid and minocycline are pharmacokinetically preferred to vancomycin in gram positive
CNS infections [20].
 56 Salma Jumaa and Rafik Karaman

Vancomycin is mainly excreted by glomerular filtration, 90% of the dose is excreted

unchanged in the urine, it is available orally and parenterally [20]. Vancomycin mean half life
is 6 hours [21].
Excessive use of vancomycin resulted in amplification of vancomycin resistant
enterococci. In addition, it caused an increase in staphylococcus resistance, which is caused

c.
by the increase in cell wall thickness and a decrease in permeability [20].
Rapid infusion of vancomycin is associated with "red man" or "red neck" syndrome, a
nonimmunological reaction which causes pruritus and hypotension.

In
This side effect can be avoided by a slow administration of the drug. Intravenous
administration is also associated with thrombophlebitis at the site of administration.
Vancomycin may cause hypersensitivity reactions which includes skin rash and drug fever.
Ototoxicity is a major toxicity caused by vancomycin. After ototoxicity the drug must be
discontinued, this side effect is reversible [22].

rs
Vancomycin has a poor oral bioavailability caused by the polar nature of the drug.
Studies have shown that the use of water in oil in water multiple emulsion incorporating
unsaturated fatty acids increased the intestinal absorption [23].

OH

he
NH2

O
OH
is
O
OH
bl
OH
O O
O
O
Pu

Cl Cl OH
HO
O
O
H H
O N
N N N NH
H O H H
HN O O O
a

OH O
NH2
HN
ov

OH

HO OH

Vancomycin
N

Figure 23. Chemical structure of vancomycin.

 Antibiotics 57

Protein Synthesis Inhibitors

This group of antibiotics targets bacterial ribosome, which composed of 50S and 70S
subunits.

c.
Tetracyclines

In
Tetracylines are lipophilic nonionized molecules composed of a linear fused six
membered nucleus (Figure 24). They have a broad spectrum of activity [24].
The first members of tetracyclines are chlortetracycline and oxytertracycline, both were
discovered in 1940 [24]. Both have a serum half life range from 6 to 10 hours, they are
absorbed in the stomach duodenum and small intestine [25].

rs
Tetracyclines are bacteriostatic to a wide range of gram positive and gram negative
bacteria, they inhibit protein synthesis by inhibiting the 30S ribosome [26].
Tetracyclines generally penetrate tissues and body fluids in a well manner. The
absorption is decreased by the presence of food, milk and calcium. They penetrate well across

he
sebum which makes tetracycline largely used for acne treatment [24].
Doxycyline and minocycline (Figure 25) are second generation tetracyclines, which have
better tissue penetration, longer half life, and large volume of distribution compared to the
original tetracylines [26]. These antibiotics can be administered once or twice daily [24].
Doxycycline has a bioavailability of more than 80%, its half life ranges from 12 to 25 hours.
is
Doxycyline is used for gonorrhea and Chlamydia pelvic infections, Lyme disease,
malaria prophylaxis and syphilis. The majority of its dose is absorbed in the duodenum, and it
is better taken with food to decrease G.I side effects [26].
bl
Tetracycline Clinical Uses
Tetracyclines generally are used for the treatment of Pasteurella infections, brucellosis,
Borrelia recurrentis that cause relapsing fever, early stages of cholera, Mycoplasma
Pu

pneumoniae infections, rickettsial infections, Shigella dysentery in which a single dose

therapy of tetracyclines is effective, Chlyamidia psittaci infections, conjunctivitis, trachoma,
L-serotypes of Chlamydia infections, ureteritis caused by Chlamydia or Ureaplasmas, syphilis
prophylaxis and chronic bronchitis in which minocycline and doxycycline are preferred [27].

N(CH3)2
a

OH
ov

CONH2

OH O OH O
N

Figure 24. Chemical structure of the minimum tetracycline pharmacophore.

 58 Salma Jumaa and Rafik Karaman

O OH O OH OH O OH O OH OH
OH OH

H2N H2N

O O

c.
H H H H
N OH N N

Doxycycline Minocycline

In
Figure 25. Chemical structures of minocycline and doxycycline.

Minocycline is preferred over doxycycline in the treatment of N. gonorrhea, Bacteroides

fragilis, S. aureus gram positive bacterial and staphylococcal skin infections. Minocycline is
also preferred for long term low dose treatment of mild to moderately severe acne caused by

rs
Corynebacterium acnes, due to its ability to penetrate quite well the lipid layers of the dermis
and possess minor side effects [27].

Tetracylines Side Effects

he
The most common side effects associated with tetracylines are G.I side effects, which
include nausea, vomiting, diarrhea and candidiasis. The most tetracycline with G.I side effects
is doxycycline. In addition, tetracyclines cause tooth discoloration in adults and children, it
can cause this discoloration in developing teeth even during pregnancy [26]. Tetracyclines
should not be used for patients less than 8 years old and pregnant women [27].
is
Resistance to Tetracyclines
The extensive use of tetracycline leads to the development of bacterial resistance, this
bl
resistance is caused by:

 Protection of the tetracycline target, ribosome.


Pu

Lowering the amount of tetracycline in the cytoplasm to prevent the tetracycline

from reaching the ribosome; this is achieved by decreasing the permeability of the
cell envelope and efflux of tetracycline outside the cytoplasm. There are two types of
tetracycline efflux pumps tetracycline specific and multidrug resistance efflux
pumps.
 Tetracycline inactivation by modifying enzymes [28].
a

The resistance and its widespread by the mobile tetracycline resistance (tet) genes caused
a decrease in the therapeutic effectiveness of tetracyclines [29], and consequently has led to
the development of the third generation tetracycline, glycylcylines. Glycylcylines have the
ov

same structural features of tetracycline, but they are not substrates for efflux pumps, which
makes this generation effective against the resistant organisms [30]. GAR639 a glycylcylines,
is an analogue of minocycline that showed in vitro activity against bacterial organisms that
are resistant to the old generation tetracyclines [31].
N

GAR639 is effective against penicillin-resistant Streptococcus pneumonia, vancomycin-

resistant enterococci and methicillin-resistant Staphylococcus aureus [29].
 Antibiotics 59

Tigycycline (GAR639) which has received FDA approval for the treatment of serious
bacterial infections is only available as injectable form administered over 1 hour period, has a
long half life of 37 to 67 hours and a large volume of distribution. Oral bioavailability of
tigycyline is reported to be limited. The most common side effects of tigycycline are nausea
and vomiting [25, 32].

c.
Aminoglycosides

In
A group of molecules that have a nucleus of amino-cyclitol attached to two or more
sugars by a glycoside linkage. They are polar and positively charged which make them
insoluble in lipid. This positive charge makes glycosides able to bind to the negatively
charged lipopolysaccharides on the bacterial cell wall, but also contributes to the side effects
of aminoglycosides [33].

rs
Clinical Uses of Aminoglycosides
Aminoglycosides have a broad spectrum of activity and rapid bactericidal effect. They

he
bind to 30S ribosome and inhibit bacterial protein synthesis. Aminoglycosides generally are
used for the treatment of aerobic gram negative bacilli, staphylococci and certain
mycobacteria. Streptomycin (Figure 26) is used for tuberculosis. Gentamicin, amikacin and
netilmicin (Figure 27) are used for pneumonia, sepsis and meningitis. Neomycin is used for
burns, wounds, ulcers and dermatitis [33].
is
Aminoglycosides are only available for parenteral, intramuscular and intravenous
administrations because they are polar compounds [33]. They are excreted unchanged in the
urine.
bl
There have been studies to increase aminoglycosides absorption using mixed micellar
solutions. It was found that the combinations of bile salts and certain lipids increased the
absorption of gentamycin and streptomycin [34].
Aminoglycosides accumulate in the renal tubules which causes nephrotoxicity. Another
Pu

common side effect is ototoxicity that can be acute, reversible, or chronic and irreversible
hearing loss which can be caused by cochlear hair cells degeneration [35].

Bacterial Resistance to Aminoglycosides

The widespread therapeutic use of aminoglycosides results in the development of
resistance. The most common mechanism of resistance is enzymatic inactivation. There are
three types of these enzymes: adenylyl transferase that adds AMP moiety, phosphotransferase
a

that adds a phosphate group to the antibiotic and acetyl transferase that adds acetyl group to
one of the amino groups of the aminoglycoside. These modifications reduce the antibiotic
ov

affinity to the RNA target and make it unable to prevent protein synthesis. Other mechanisms
of resistance are target modification, 16s rRNA methylation and mutations of the ribosome
target, and efflux pumps that prevent the antibiotic from reaching the cytoplasm where is the
target site [33, 36].
N
 60 Salma Jumaa and Rafik Karaman

NH2

H2N HN OH
N
HO

c.
O OH
O
O
N
O OH

In
O
OH
H2N HO OH
NH2

Streptomycin

rs
Figure 26. Chemical structure of streptomycin.
OH H2N

HN

HO
O

O he
HO O

NH2
O

NH
is
H2N
bl
Gentamicin

HO O
Pu

NH

H2N

H2N H2N O OH

HO O OH O NH2
a

HO OH OH
ov

OH
Amikacin

Figure 27. (Continued).

N
 Antibiotics 61

NH

c.
H2N H2N O OH

O OH O NH

In
OH
NH2
Netilimicin

rs
Figure 27. Chemical structures of gentamicin, amikacin and netilmicin.

Macrolides

he
Erythromycin (Figure 28) was the first antibiotic discovered in 1952 among this group.
After its discovery many semisynthetic compounds were developed such as clarithromycin,
azithromycin and roxithromycin that are all derivatives of erythromycin with better
microbiological and pharmacokinetic properties. The general structure of macrolides is a 12
is
to 16 atoms lactone ring that is attached via a glycosidic linkage to one or more sugars.
Macrolides bind to 50S ribosome and inhibit protein synthesis [37].
Macrolides are widely used for the treatment of gram positive bacterial infections such as
bl
Staphylococcus aureus and Staphylococcus pneumonia.

Erythromycin
Erythromycin (Figure 28) is a 14-membered lactone ring attached to two sugars. It is
Pu

used for M. pneumonia and Legionella pneumonia infections, diphtheria, pertussis,

conjunctivitis and bacillary angiomatosis. Erythromycin is well absorbed from the G.I,
excreted primarily in the bile, has a half life of 1.4 hours, inhibits CYP450 enzymes and is
available for oral and intravenous administration. The main side effects of erythromycin are
nausea, vomiting, diarrhea, abdominal cramps and phlebitis caused by intravenous
administration [38].
a

Clarithromycin
Clarithromycin is a 14-membered lactone ring, a derivative of erythromycin. It has the
ov

best absorption from the G.I of all macrolides with 50% bioavailability, administered twice
daily and not available for intravenous administration. Clarithromycin is excreted in the urine
after extensive hepatic metabolism. It is used for the treatment of upper and lower respiratory
tract infections [38]. Clarithromycin is also widely used for H. pylori infections [39].
N
 62 Salma Jumaa and Rafik Karaman

HO

c.
O
O

In
O

O OH
HO
OH

rs
HO
O N

he
O

Erythromycin
is
Figure 28. Chemical structure of erythromycin.

Clarithromycin is well tolerated in doses less than 2000 mg, but it occasionally causes
nausea, diarrhea, abdominal pain, headache and metallic taste. This antibiotic causes drug-
bl
drug interactions as a result of inhibiting the CYP450 enzymes [38].

Azithromycin
Pu

Azithromycin (Figure 29) is the only 15 membered lactone ring antibiotic of this group. It
was developed by the addition of amino group to the erythromycin ring and it has a better
gram negative bacterial activity than erythromycin [37]. It is the most active macrolides
against H. Influenza and Legionella species. Azithromycin has an oral bioavailability of 37%.
It is used as single dose therapy for STDs and short duration of therapy of 3-5 days for skin,
soft tissue and some respiratory tract infections because its concentration remains high in
these tissues for extended period of time [38]. Azithromycin is excreted unchanged in the
a

feces [40].
Azithromycin side effects are mild to moderate. The primary side effects are
gastrointestinal including nausea diarrhea and mild abdominal pain [41].
ov

Resistance to Macrolides
Resistance to macrolides is accomplished by methylation of the adenine in the 23S
rRNA, decrease in the drug penetration and enzymatic degradation [41].
N
 Antibiotics 63

OH

c.
O

In
O
O

OH

rs
HO O

HO OH

N O

he N
is
Azithromycin
Figure 29. Chemical structure of azithromycin.
bl

Chloramphenicol
Pu

Chloramphenicol (Figure 30) was the first broad spectrum antibiotic, it is water insoluble
and has extremely bitter taste. The modified forms of chloramphenicol are available for oral
and parenteral administration [42]. Chloramphenicol palmitate is available as suspension and
capsules for oral administration and chloramphenicol sodium succinate is available for
intravenous administration [43]. The bacteriostatic effect of chloramphenicol is a result of
protein synthesis inhibition by binding to 50S ribosomal subunit [44].
a

Because of chloramphenicol toxicity and the availability of safer alternatives

chloramphenicol use is limited. It is used only in life-threatening situations.
Chloramphenicol is associated with fatal toxicities including aplastic anemia, that can't be
ov

predicted and occurs weeks or months after treatment, and gray baby syndrome in infants and
newborns. This syndrome consists of cyanosis, abdominal distention and vasomotor collapse.
Another serious toxicity is bone marrow suppression, which is reversible and dose related
[43].
N
 64 Salma Jumaa and Rafik Karaman

OH

HO

O NH O-

c.
+
N

In
Cl Cl

Chloramphenicol
Figure 30. Structure of chloramphenicol.

rs
Clindamycin

he
Clindamycin was introduced into clinical practice in 1960, derived from lincomycin [43].
Clindamycin (Figure 31) is available orally as capsules as clindamycin hydrochloride and
suspension as clindamycin palmitate, It is available as clindamycin phosphate for
intramuscular and intravenous administration. It is well absorbed orally and not significantly
affected by food [45].
is
The half life of clindamycin is 2 to 4 hours and it is metabolized in the liver then excreted
in the urine and feces [46].
Clindamycin inhibits protein synthesis by binding to 50S ribosomal subunit [47]. It is
active against anaerobic gram positive and gram negative bacteria [48]. A common
bl
complication of clindamycin that limits its use is C. difficile toxin-mediated
pseudomembranous colitis, which can be treated by discontinuation of clindamycin and
initiation of vancomycin or metronidazole. Other less serious side effects are nausea,
Pu

vomiting, flatulence, anorexia, bitter taste, abdominal distention and transient increase in
hepatocellular enzymes [47, 48].

HO
a

O
H
N
ov

HO N

OH O
Cl
N

Clindamycin
Figure 31. Chemical structure of clindamycin.
 Antibiotics 65

DNA Synthesis Inhibitors, Folic Acid Antagonists

and Urinary Tract Antiseptics
Fluoroquinolones

c.
Quinolones were derived from quinine. Figure 32 shows the basic chemical structure of
fluoroquinolones. Nalidixic acid (Figure 33) was the first fluoroquinolone developed. It has a
variable systemic absorption, therefore, its use was limited to urinary tract infections [49].

In
Later on, norfloxacin was developed by the addition of piperazine group at quinolone‘s C7
(Figure 34), followed by ciprofloxacin which has a broader spectrum of activity [50].

R5 O O

rs
F
OH

R7 X8 he N R2
is
R1
bl
Figure 32. The basic pharmacore of fluoroquinolones.
Pu

N N

OH
a
ov

O O
Nalidixic acid
N

Figure 33. Chemical structure of nalidixic acid.

 66 Salma Jumaa and Rafik Karaman

O O

F
HO

c.
N N

In
NH

Norfloxacin

rs
Figure 34. Chemical structure of norfloxacin.

Quinolones interact with two targets, DNA gyrase and topoisomerase IV. They are both
essential for bacterial DNA replication, by binding to these targets quinolones disrupt DNA

he
synthesis and cause cell death [51, 52].

Fluoroquinolones Clinical Uses

Fluoroquinolones are very active against enteric gram negative bacilli and cocci, gram
negative bacteria, gastrointestinal tract and urinary tract bacterial pathogens, while ofloxacin
is
and ciprofloxacin are preferred for gram positive bacterial infections [53].

Ciprofloxacin
Ciprofloxacin was developed by the addition of cyclopropyl group to the N1 quinolone
bl
position (Figure 35), this modification increased the potency of the drug [49]. It has a half life
of 3.5 hours, well absorbed and has a bioavailability of 70% [50]. It is used for gram negative
bacterial infections and as an anti-pseudomonal agent [49].
Pu

O O

F
HO
a

N N
ov

NH

Ciprofloxacin
N

Figure 35. Chemical structure of ciprofloxacin.

 Antibiotics 67

The new fluoroquinolones include clinafloxacin, gatifloxacin, gemifloxacin,

grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin that
are well absorbed after oral administration, have good tissue penetration and their
bioavailability ranges from 70% to 99%. They have a longer half life than ciprofloxacin and
they are effective in the treatment of respiratory tract infections including community

c.
acquired pneumonia, acute exacerbation of chronic bronchitis and acute sinusitis [50].

Levofloxacin

In
Levofloxacin was developed by the alkylation on position 8 of quinolone (Figure 36).
This modification increased the half life of the drug to 7 hours and improved its tissue
penetration. Levofloxacin is widely used for respiratory tract infections [49]. The absorption
of this drug is rapid and its bioavailability is about 100% [54]. Levofloxacin is mainly
eliminated renally and less than 10% of the dose is excreted by metabolism [55].

rs
O O

he
OH

N N
is
N O
bl

Levofloxacin
Pu

Figure 36. Chemical structure of levofloxacin.

Fluoroquinolones Side Effects

The most common adverse effects of fluoroquinolones are gastrointestinal including
nausea, vomiting and diarrhea. Central nervous system adverse effects primarily headache
and dizziness, pruritus and skin rash [56, 57]. These side effects are generally mild and
reversible. Sparfloxacin and grepafloxacin were withdrawn from the market because of
a

cardiovascular side effects, due to prolongation of the QT interval [50].

All Fluoroquinolones are contraindicated in paediatric patients because of side effects
ov

[50].

Sulfonamides
N

Sulfonamides are broad spectrum antibiotics that are active against both gram negative
and positive bacteria. They inhibit the synthesis of folic acid leading to their bacteriostatic
effect. They are generally well absorbed from the G.I and metabolized in the liver [58].
 68 Salma Jumaa and Rafik Karaman

Sulfamethoxazole-Trimethoprime Combination (Co-Trimoxazole)

The Sulfamethoxazole trimethoprime combination (Figure 37) act synergistically in

killing bacteria. This combination is available for oral and intravenous administration. They
are both well absorbed from the G.I, trimethoprim is mainly excreted renally while

c.
sulfamethoxazole is primarily metabolized in the liver [59].

NH2
O

In
O O

rs
O S O

N NH

he
N
O

H2N N NH2
is
Sulfamethoxazole Trimethoprime
Figure 37. Chemical structures of sulfamethoxazole and trimethoprime.
bl
Mechanism of Action
Sulfamethoxazole is a sulfonamide drug that is similar in structure to para-aminobenzoic
acid. It inhibits dihydrobtroate synthetase enzyme and prevent the synthesis of dihydrofolic
Pu

acid from its precursor. Trimethoprim inhibits dihydrofolate reductase enzyme and prevents
the synthesis of the active tetrahydrofolic acid from dihydrofolic acid. Inhibition of these two
steps blocks the synthesis of porins, thymidine and bacterial DNA [58, 59].
The most common use of sulfamethoxazole-trimethoprime combination is in urinary tract
infections, it is also effective in lower and upper respiratory tract infections [58].
The most common side effects are gastrointestinal including nausea, vomiting and
a

anorexia, and hypersensitivity skin reactions [58, 59].

ov

Nitrofurantoin
This antimicrobial became available for clinical use in 1953. Nitrofurantoin (Figure 38) is
effective in the treatment of lower UTI. It achieves therapeutically active concentrations only
N

in the urinary tract, which makes it a target selective drug and does not change the normal
flora growth. Nitrofurantoin does not reach effective concentration in the blood and its side
effects are rare except for the pulmonary reaction that is rare [60].
 Antibiotics 69

O
O-
NH
N+
O O N N

c.
O

In
Nitrofurantoin

rs
Figure 38. Chemical structure of nitrofurantoin.

Summary and Conclusion

he
Antibiotics contributed over years in bacterial infections control. These drugs have an
important role in the rise of life expectancy. Despite all the developments in antibiotic
industry, infectious diseases remain the second cause of death worldwide; this is due to the
development of antibiotics resistance organisms, which decreased current antibiotics
is
effectiveness. The development of new antibiotics have slowed and since 1970 only three
new classes of antibiotics have been marketed [61].
The majority of antibiotics is considered safe, but any antibiotic can cause side effects
bl
and in some cases life threatening side effects. β-lactams and sulfamethoxazole cause
leukopnia, thrombocytopenia, anemia and skin rash. In addition, both antibacterial groups
cause hypersensitivity reactions including drug fever. β-lactams are the most frequent
Pu

antibiotic class associated with anaphylactic reaction. Photosensitivity reaction is a common

side effect of tetracycline and sparfloxacin. Erythromycin and some quinolones cause
prolongation of QT interval. Generally antimicrobials cause G.I side effects; macrolides are
the least orally tolerated. Most antibiotic associated side effects are reversible [62].
Resistance to antibiotics is caused by many mechanisms including decrease in antibiotic
diffusion through the glycocalyx diffusion layer, that acts like a bacterial barrier to the
antimicrobial agents, enzymatic degradation of the antibiotic such as β-lactamases that
a

hydrolyze the β-lactam ring of penicillins, cephalosporins and related drugs, the gram
negative cell envelope that prevents the drug from reaching inside the cell, bacterial
adaptation as a result of exposure to sub-inhibitory concentrations of antibiotics, such as the
ov

alteration in the penicillin binding proteins structure that decrease the affinity of penicillin to
the target site and decrease in the antibiotic concentration that reaches the target site because
of increase or decrease in certain outer membrane proteins and multidrug efflux pumps
[63, 64].
N

New antibiotics are needed to treat infections caused by resistant pathogens. There are
two strategies for the development of new antibiotics: (1) to modify the existing scaffolds by
modifying chemical groups at the periphery of the core structure and (2) to develop a new
 70 Salma Jumaa and Rafik Karaman

scaffold such as phytochemicals, that are derived from plants [65]. These scaffolds must be
active against gram positive and negative bacteria, have no cross resistance with the existing
antibiotics and be easily synthesized [30].

c.
References
[1] Schwartz, R. S. (2004) Paul Ehrlich's magic bullets. The New England Journal of

In
Medicine, 350(11), 1079-80.
[2] Aminov, R. I. (2010) A brief history of the antibiotic era: lessons learned and
challenges for the future. Frontiers in Microbiololgy, 1, 134.
[3] Abraham, E., (1983) History of β-lactam antibiotics, in Antibiotics. Antibiotics (pp. 1-
14), Springer Berlin Heidelberg.

rs
[4] Zaffiri, L., Gardner, J. and Toledo-Pereyra, L. H. (2012) History of antibiotics. From
salvarsan to cephalosporins. Journal of Investigative Surgery, 25(2), 67-77.
[5] Schatz, A., Bugie, E. and Waksman, S. A. (2005) Streptomycin, a substance exhibiting
antibiotic activity against gram-positive and gram-negative bacteria. 1944.

he
Experimental Biology and Medicine, (437), 3-6.
[6] Waxman, D. J. and Strominger, J. L. (1983) Penicillin-binding proteins and the
mechanism of action of beta-lactam antibiotics. Annual Review of Biochemistry, 52,
825-69.
[7] Blumberg, P. M. and Strominger, J. L. (1974) Interaction of penicillin with the bacterial
is
cell: penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriological
Reviews, 38(3), 291-335.
[8] Silver, L. L. (2003) Novel inhibitors of bacterial cell wall synthesis. Current Opinion in
bl
Microbiology, 6(5), 431-8.
[9] Miller, E. L. (2002) The penicillins: a review and update. Journal of Midwifery and
Women's Health, 47(6), 426-34.
[10] Ball, A. (1982) Clinical uses of penicillins. The Lancet, 320(8291), 197-199.
Pu

[11] Drawz, S. M. and Bonomo, R. A. (2010) Three decades of beta-lactamase inhibitors.

Clinical Microbiology Reviews, 23(1), 160-201.
[12] Marshall, W. F. and Blair, J. E. (1999) The cephalosporins. Mayo Clinic Proceedings,
74(2), 187-95.
[13] Gozzard, D. I., Geddes, A. M., Farrell, I. D., Eykyn, S. J., Phillips, I., Wise, R.
andBrown, R. M. (1982) Ceftazidime-a new extended-spectrum cephalosporin. Lancet,
a

1(8282), 1152-6.
[14] Wilson, W. R. (1998) The role of fourth-generation cephalosporins in the treatment of
serious infectious diseases in hospitalized patients. Diagnostic microbiology and
ov

infectious disease, 31(3), 473-477.

[15] Guay, D. R. (2002) Cefdinir: an advanced-generation, broad-spectrum oral
cephalosporin. Clinical Therapeutics, 24(4), 473-89.
[16] Karaman, R. (2014). Prodrugs for Masking the Bitter Taste of Drugs. Application of
Nanotechnology in Drug Delivery.
N

[17] Bonfiglio, G., Russo, G. and Nicoletti, G. (2002) Recent developments in carbapenems.
Expert Opinion on Investigational Drugs, 11(4), 529-44.
 Antibiotics 71

[18] Reynolds, P. E. (1989) Structure, biochemistry and mechanism of action of

glycopeptide antibiotics. European Journal of Clinical Microbiology and Infectous
Diseases, 8(11), 943-50.
[19] Barna, J. C. and Williams, D. H. (1984) The structure and mode of action of
glycopeptide antibiotics of the vancomycin group. Annual Reviews in Microbiology,

c.
38(1), 339-57.
[20] Cunha, B. A. (2008) Vancomycin revisited: a reappraisal of clinical use. Critical Care
Clinics, 24(2), 393-420, x-xi.

In
[21] Grayson, M. L. (2010) Kucers' the Use of Antibiotics: A Clinical Review of
Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs. Hodder Arnold London
United Kingdom.
[22] Hermans, P. E. and Wilhelm, M. P. (1987) Vancomycin. Mayo Clinc Proceedings,
62(10), 901-5.

rs
[23] Kajita, M., Morishita, M., Takayama, K., Chiba, Y., Tokiwa, S. and Nagai, T. (2000)
Enhanced enteral bioavailability of vancomycin using water-in-oil-in-water multiple
emulsion incorporating highly purified unsaturated fatty acid. Journal of
Pharmaceutical Sciences, 89(10), 1243-52.

he
[24] Chopra, I. and Roberts, M. (2001) Tetracycline antibiotics: mode of action,
applications, molecular biology, and epidemiology of bacterial resistance. Microbiology
and Molecular Biology Reviews, 65(2), 232-60.
[25] Agwuh, K. N. and MacGowan, A. (2006) Pharmacokinetics and pharmacodynamics of
the tetracyclines including glycylcyclines. Journal of Antimicrobial Chemotherapy,
is
58(2), 256-65.
[26] Sloan, B. and Scheinfeld, N. (2008) The use and safety of doxycycline hyclate and
other second-generation tetracyclines.
bl
[27] Cunha, B. (1985). Clinical uses of the tetracyclines, in The tetracyclines (pp. 393-404).
Springer Berlin Heidelberg.
[28] Schnappinger, D. and Hillen, W. (1996) Tetracyclines: antibiotic action, uptake, and
resistance mechanisms. Archeives of Microbiology, 165(6), 359-69.
Pu

[29] Projan, S. J. (2000) Preclinical pharmacology of GAR-936, a novel glycylcycline

antibacterial agent. Pharmacotherapy, 20(9 Pt 2), 219S-223S.
[30] Fischbach, M. A. and Walsh, C. T. (2009) Antibiotics for emerging pathogens. Science,
325(5944), 1089-93.
[31] Chopra, I. (2001) Glycylcyclines: third-generation tetracycline antibiotics. Current
Opinion in Pharmacology, 1(5), 464-9.
[32] Noskin, G. A. (2005) Tigecycline: a new glycylcycline for treatment of serious
a

infections. Clinical Infectous Diseases, 41 (Supplement 5), S303-14.

[33] Jana, S. and Deb, J. K. (2006) Molecular understanding of aminoglycoside action and
ov

resistance. Applied Microbiology and Biotechnology, 70(2), 140-50.

[34] Shozo, M., Noriyuki, M. and Hitoshi, S. (1979) Improvement of absolute
bioavailability of normally poorly absorbed drugs: inducement of the intestinal
absorption of streptomycin and gentamycin by lipid-bile salt mixed micelles in rat and
rabbit. International Journal of Pharmaceutics, 2(2), 101-111.
N

[35] Begg, E. J. and Barclay, M. L. (1995) Aminoglycosides-50 years on. Britich Journal of
Clinical Pharmacology, 39(6), 597-603.
 72 Salma Jumaa and Rafik Karaman

[36] Walsh, C. (2000) Molecular mechanisms that confer antibacterial drug resistance.
Nature, 406(6797), 775-81.
[37] Mazzei, T., Mini, E., Novelli, A. and Periti, P. (1993) Chemistry and mode of action of
macrolides. Journal of Antimicrobial Chemotherapy, 31 Suppl. C., 1-9.
[38] Alvarez-Elcoro, S. and Enzler, M. J. (1999) The macrolides: erythromycin,

c.
clarithromycin, and azithromycin. Mayo Clinic Proceedings, 74(6), 613-34.
[39] Graham, D. Y., Opekun, A. R. and Klein, P. D. (1993) Clarithromycin for the
eradication of Helicobacter pylori. Journal of clinical gastroenterology, 16(4), 292-294.

In
[40] Lode, H., Borner, K., Koeppe, P. and Schaberg, T. (1996) Azithromycin—review of
key chemical, pharmacokinetic and microbiological features. Journal of Antimicrobial
Chemotherapy, 37(suppl. C.), 1-8.
[41] Drew, R. H. and Gallis, H. A. (1992) Azithromycin-spectrum of activity,
pharmacokinetics, and clinical applications. Pharmacotherapy, 12(3), 161-73.

rs
[42] Feder, H. M., Jr., Osier, C. and Maderazo, E. G. (1981) Chloramphenicol: A review of
its use in clinical practice. Review Of Infectous Diseases, 3(3), 479-91.
[43] Smilack, J. D., Wilson, W. R. and Cockerill, F. R. (1991) Tetracyclines,
chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clinic

he
Proceedings, 66(12), 1270-80.
[44] Cundliffe, E. and McQuillen, K. (1967) Bacterial protein synthesis: the effects of
antibiotics. Journal of molecular biology, 30(1), 137-146.
[45] Phillips, I. (1971) Clinical uses and control of rifampicin and clindamycin. Journal of
Clinical Pathology, 24(5), 410-8.
is
[46] Lell, B. and Kremsner, P. G. (2002) Clindamycin as an antimalarial drug: review of
clinical trials. Antimicrobial Agents And Chemotherapy, 46(8), 2315-20.
[47] Dhawan, V. K. and Thadepalli, H. (1982) Clindamycin: a review of fifteen years of
bl
experience. Review of Infectious Diseases, 4(6), 1133-1153.
[48] Kasten, M. J. (1999) Clindamycin, metronidazole, and chloramphenicol. Mayo Clinic
Proceedings, 74(8), 825-33.
[49] Andersson, M. I. and MacGowan, A. P. (2003) Development of the quinolones. Jornal
Pu

of Antimicrobial Chemotherapy, 51 Suppl. 1, 1-11.

[50] Zhanel, G. G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A. S., Embil, J., Smith, H. and
Hoban, D. J. (2002) A critical review of the fluoroquinolones: focus on respiratory
infections. Drugs, 62(1), 13-59.
[51] Bearden, D. T. and Danziger, L. H. (2001) Mechanism of action of and resistance to
quinolones. Pharmacotherapy, 21(10 Pt 2), 224S-232S.
[52] Hooper, D. C. (2001) Mechanisms of action of antimicrobials: focus on
a

fluoroquinolones. Clinical Infectious Diseases, 32(Supplement 1), S9-S15.

[53] Wolfson, J. S. and Hooper, D. C. (1985) The fluoroquinolones: structures, mechanisms
ov

of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and
Chemotherapy, 28(4), 581-6.
[54] Norrby, S. R. (1999) Levofloxacin. Expert opinion on pharmacotherapy, 1(1), 109-119.
[55] Turnidge, J. (1999) Pharmacokinetics and pharmacodynamics of fluoroquinolones.
Drugs, 58 (Supplement 2), 29-36.
N

[56] Ball, P. and Tillotson, G. (1995) Tolerability of fluoroquinolone antibiotics. Drug

safety, 13(6), 343-358.
 Antibiotics 73

[57] Bertino, J., Jr. and Fish, D. (2000) The safety profile of the fluoroquinolones. Clinical
Therapeutics, 22(7), 798-817.
[58] Connor, E. E. (1998) Sulfonamide antibiotics. Primary care update for ob/gyns, 5(1),
32-35.
[59] Masters, P. A., O'Bryan, T. A., Zurlo, J., Miller, D. Q. and Joshi, N. (2003)

c.
Trimethoprim-sulfamethoxazole revisited. Archives of internal medicine, 163(4), 402-
410.
[60] Cunha, B. A. (1988) Nitrofurantoin--current concepts. Urology, 32(1), 67-71.

In
[61] Butler, M. S. and Buss, A. D. (2006) Natural products-the future scaffolds for novel
antibiotics? Biochemical Pharmacology, 71(7), 919-29.
[62] Cunha, B. A. (2001) Antibiotic side effects. Medical Clinics of North America, 85(1),
149-85.
[63] Cloete, T. E. (2003) Resistance mechanisms of bacteria to antimicrobial compounds.

rs
International Biodeterioration and Biodegradation, 51(4), 277-282.
[64] Gold, H. S. and Moellering, R. C., Jr. (1996) Antimicrobial-drug resistance. New
England Journal of Medicine, 335(19), 1445-53.
[65] Mandal, S. M., Roy, A., Ghosh, A. K., Hazra, T. K., Basak, A. and Franco, O. L. (2014)

he
Challenges and future prospects of antibiotic therapy: from peptides to phages
utilization. Frontiers in Pharmacology, 5.
is
bl
Pu
a
ov
N
 c.
In
rs
he
is
bl
Pu
a
ov
N

View publication stats